StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Several other research analysts also recently issued reports on the stock. Brookline Capital Management downgraded shares of Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Maxim Group downgraded shares of Oncternal Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 4th. Cantor Fitzgerald downgraded shares of Oncternal Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, April 6th. Brookline Capital Acquisition reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Tuesday, April 4th. Finally, HC Wainwright downgraded shares of Oncternal Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, April 4th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat.com, Oncternal Therapeutics has a consensus rating of “Hold” and an average target price of $5.77.

Oncternal Therapeutics Price Performance

NASDAQ ONCT opened at $0.29 on Monday. Oncternal Therapeutics has a 12 month low of $0.26 and a 12 month high of $1.87. The company has a market capitalization of $16.79 million, a price-to-earnings ratio of -0.34 and a beta of 1.55. The firm’s fifty day moving average price is $0.51 and its 200 day moving average price is $0.84.

Insider Transactions at Oncternal Therapeutics

In other news, CEO James B. Breitmeyer bought 100,000 shares of the firm’s stock in a transaction dated Thursday, April 13th. The stock was acquired at an average cost of $0.29 per share, for a total transaction of $29,000.00. Following the completion of the purchase, the chief executive officer now owns 146,544 shares of the company’s stock, valued at $42,497.76. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders acquired 160,000 shares of company stock valued at $46,650 over the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Oncternal Therapeutics by 34.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,863,217 shares of the company’s stock valued at $2,553,000 after acquiring an additional 728,200 shares during the last quarter. Millennium Management LLC lifted its position in shares of Oncternal Therapeutics by 187.9% in the 2nd quarter. Millennium Management LLC now owns 1,296,115 shares of the company’s stock worth $1,439,000 after buying an additional 845,991 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Oncternal Therapeutics by 52.2% in the 3rd quarter. Renaissance Technologies LLC now owns 979,800 shares of the company’s stock worth $874,000 after acquiring an additional 336,066 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Oncternal Therapeutics in the 1st quarter worth about $585,000. Finally, Two Sigma Investments LP increased its holdings in shares of Oncternal Therapeutics by 136.0% in the 3rd quarter. Two Sigma Investments LP now owns 356,244 shares of the company’s stock worth $318,000 after acquiring an additional 205,312 shares during the period. 16.66% of the stock is currently owned by institutional investors.

About Oncternal Therapeutics

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.